S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

$267.04
+8.23 (+3.18%)
(As of 03/28/2024 ET)
Today's Range
$254.75
$268.22
50-Day Range
$171.37
$283.23
52-Week Range
$119.76
$322.67
Volume
441,995 shs
Average Volume
725,066 shs
Market Capitalization
$5.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$377.40

Madrigal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
41.3% Upside
$377.40 Price Target
Short Interest
Healthy
20.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.78mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($21.48) to ($13.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.91 out of 5 stars

Medical Sector

27th out of 939 stocks

Pharmaceutical Preparations Industry

14th out of 444 stocks

MDGL stock logo

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock Price History

MDGL Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (MDGL)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
MDGL May 2024 390.000 call
MDGL May 2024 350.000 call
MDGL May 2024 230.000 put
MDGL Jun 2024 410.000 put
MDGL May 2024 260.000 put
Madrigal Pharmaceuticals (NASDAQ:MDGL) PT Raised to $389.00
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
376
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$377.40
High Stock Price Target
$425.00
Low Stock Price Target
$270.00
Potential Upside/Downside
+41.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-373,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$20.53 per share

Miscellaneous

Free Float
15,138,000
Market Cap
$5.31 billion
Optionable
Optionable
Beta
-0.48

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 72)
    Founder, Chief Medical Officer, President of Research & Development and Director
    Comp: $939.83k
  • Mr. Alex G. Howarth (Age 54)
    Senior VP & CFO
    Comp: $757.26k
  • Mr. Brian J. Lynch J.D. (Age 62)
    Senior VP & General Counsel
    Comp: $763.75k
  • Mr. William J. Sibold (Age 58)
    CEO, President & Director
  • Mr. Ronald Filippo
    Chief Information Officer
  • Ms. Tina E. Ventura
    Chief Investor Relations Officer
  • Dr. Kianoush Motesharei Ph.d. (Age 54)
    Senior Vice President of Business & Corporate Development
  • Mr. Clint Wallace
    Chief Human Resources Officer
  • Mr. Edward Chiang
    Senior Vice President of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Senior Vice President of Clinical Management

MDGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price target for 2024?

10 brokers have issued 12 month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price targets range from $270.00 to $425.00. On average, they expect the company's share price to reach $377.40 in the next twelve months. This suggests a possible upside of 41.3% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2024?

Madrigal Pharmaceuticals' stock was trading at $231.38 at the beginning of 2024. Since then, MDGL stock has increased by 15.4% and is now trading at $267.04.
View the best growth stocks for 2024 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.26) by $0.42. During the same period in the prior year, the company posted ($4.98) EPS.

What ETFs hold Madrigal Pharmaceuticals' stock?
What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.57%), Vanguard Group Inc. (7.98%), Vanguard Group Inc. (7.91%), Paulson & CO. Inc. (5.60%), RTW Investments LP (4.13%) and Price T Rowe Associates Inc. MD (1.97%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, Remy Sukhija, Richard S Levy and Robert E Waltermire.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDGL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners